MedTrace Logo

Brain, Gut and Kidney Blood Flow During Medical Closure of PDA

NCT00554307 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2015-01-26

No results posted yet for this study

Summary

The purpose of this study is to determine how the medications which are used to close the patent ductus arteriosus (PDA) in preterm infants affect brain, kidney and gut blood flow when compared to infants that are not treated with these medications. The medications being used for PDA closure are indomethacin and neoprofen.

Conditions

  • Patent Ductus Arteriosus

Interventions

DEVICE

INVOS Cerebral/Somatic oximeter

Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • University of Louisville

    lead OTHER

Principal Investigators

  • Dan L Stewart, MD · University of Louisville

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00554307 on ClinicalTrials.gov